Company news
BioVie Inc. news in 2025
BioVie Inc.'s news releases, calls and decks from 2025, newest first.
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics
December 17, 2025
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9
November 19, 2025
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
September 26, 2025
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
August 13, 2025
BioVie Inc. Announces Closing of $12 Million Public Offering
August 11, 2025
BioVie Inc. Announces Pricing of $12 Million Public Offering
August 7, 2025
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
July 24, 2025
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
July 22, 2025
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
July 9, 2025
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
June 26, 2025
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
June 24, 2025
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 15, 2025
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
May 14, 2025
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
May 7, 2025
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
May 5, 2025
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
April 16, 2025
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
March 27, 2025
Decks in 2025
- Longevity Biotech, Boston, MA (October 2025)
Conference · 22 slides · Oct 23, 2025